Kiora Pharmaceuticals Granted U.S. And European Patents For Local Ocular Delivery Of The KIO-100 Family Of Compounds
Portfolio Pulse from Charles Gross
Kiora Pharmaceuticals, Inc (NASDAQ:KPRX) has been granted U.S. and European patents for local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules. This extends market exclusivity for approved indications in the U.S. and Europe. The company's KIO-104 product demonstrated promising results in a Phase 1b clinical study.
August 23, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kiora Pharmaceuticals has been granted patents for the KIO-100 family of compounds, which could extend its market exclusivity and potentially boost its stock.
The granting of patents for Kiora's KIO-100 family of compounds extends its market exclusivity in the U.S. and Europe. This could lead to increased revenues and profitability, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100